MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...
Contrary to what we are led to believe, investors can only spend compound returns, not average returns. Nevertheless, the average returns are so often mentioned by those seeking to promote an ...
A growing body of research suggests that exposure to PFAS, commonly called "forever chemicals," may increase a person's risk of developing cancer.
Government plays down threat from foiled attack Prosecutor says 18 assailants dead and six wounded Attack comes after Chad scrapped defence pact with France Security sources and experts say ...
Protesters supporting and opposing Yoon braved freezing temperatures to stage rallies on the streets around the presidential compound on Wednesday after a court re-issued a warrant on Tuesday to ...
Along with a third ODD in glioblastoma, the FDA has clearly recognized THIO’s potential as an effective treatment for multiple cancer indications. Comparatively, most oncology compounds at this ...
MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, its small molecule telomere-targeting anticancer agent ...
Along with a third ODD in glioblastoma, the FDA has clearly recognized THIO’s potential as an effective treatment for multiple cancer indications. Comparatively, most oncology compounds at this stage ...
Copyright 2025 The Associated Press. All Rights Reserved. A TV screen shows a file image of South Korean President Yoon Suk Yeol as supporters of impeached Yoon stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback